EAN 2026 | COMT inhibitors as an adjunct to manage OFF periods in Parkinson’s disease

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, shares insights into the value of catechol-O-methyltransferase (COMT) inhibition for managing OFF periods in Parkinson’s disease (PD), particularly when combined with dopa decarboxylase inhibition. Prof. Antonini highlights that blocking both pathways can improve the stability of levodopa plasma levels, allowing patients to experience a better quality of life. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.